Monopar Therapeutics Inc. (MNPR), a clinical-stage radiopharma company, is scheduled to present additional data from its phase I imaging and dosimetry clinical trial of imaging agent MNPR-101-Zr at the upcoming European Association of Nuclear Medicine 2024 Annual Congress to be held in Hamburg, Germany on October 19-23, 2024.
MNPR-101-Zr is a zirconium-89 (imaging radioisotope) labeled version of MNPR-101, the company's proprietary first-in-class humanized monoclonal antibody. MNPR-101 targets the urokinase plasminogen activator receptor (uPAR), which is expressed in numerous tumor types including pancreatic, breast, colorectal, and bladder.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.